Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-08-03 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on August 12, 2020, inter alia, to consider the following items of businesses ....
Regulatory Filings
2020-08-03 English
Closure of Trading Window
Regulatory Filings
2020-08-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice from the company to stock exchanges about an upcoming Board Meeting scheduled for August 12, 2020. The agenda includes consideration of unaudited financial results for the quarter ended June 30, 2020, and consideration of an interim dividend. The document also mentions the closure of the trading window for insiders. The document is short (1726 characters) and serves as an announcement of a future event (Board Meeting) rather than containing actual financial results or detailed reports. It is not a financial report itself but a regulatory announcement about the meeting where such reports will be considered. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-03 English
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2020 ,inter alia, to consider and approve To consider Un-audited Financial ....
Regulatory Filings
2020-08-03 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for August 12, 2020, to consider un-audited financial results for the quarter ended June 30, 2020, and interim dividend. It is addressed to stock exchanges and mentions SEBI regulations. The document is short (1726 characters) and serves as an announcement of the upcoming board meeting and agenda items, not the actual financial report or results. Therefore, it is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain substantive financial data or the report itself.
2020-08-03 English
Related Party Transactions for the FY ended 2019-2020
Regulatory Filings
2020-07-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.